{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T07:46:03Z","timestamp":1790063163455,"version":"4.0.1"},"reference-count":87,"publisher":"Becaris Publishing Limited","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:p>\n            <jats:bold>Aim:<\/jats:bold>\n            The six-minute walk test (6MWT) is a\u00a0common measure of functional capacity in patients with heart failure (HF). Primary clinical study end points in cardiomyopathy (CM) trials, including transthyretin-mediated amyloidosis with CM (ATTR-CM), are often limited to hospitalization and mortality.\n            <jats:bold>Objective:<\/jats:bold>\n            To investigate the relationship between the 6MWT and hospitalization or mortality in CM, including ATTR-CM.\n            <jats:bold>Method:<\/jats:bold>\n            A PRISMA-guided systematic literature review was conducted using search terms for CM, 6MWT, hospitalization and mortality.\n            <jats:bold>Results:<\/jats:bold>\n            Forty-one studies were identified that reported 6MWT data and hospitalization or mortality data for patients with CM. The data suggest that a greater 6MWT distance is associated with a reduced risk of hospitalization or mortality in CM.\n            <jats:bold>Conclusion:<\/jats:bold>\n            The 6MWT is an accepted alternative end point in CM trials, including ATTR-CM.\n          <\/jats:p>","DOI":"10.57264\/cer-2023-0158","type":"journal-article","created":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T15:18:45Z","timestamp":1718291925000},"source":"Crossref","is-referenced-by-count":7,"title":["Six-minute walk test as clinical end point in cardiomyopathy clinical trials, including ATTR-CM: a systematic literature review"],"prefix":"10.57264","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5481-2122","authenticated-orcid":false,"given":"Jose","family":"Nativi-Nicolau","sequence":"first","affiliation":[{"name":"Department\u00a0of Transplant, Mayo Clinic,\u00a0Jacksonville, FL 32224, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4526-8679","authenticated-orcid":false,"given":"Ali","family":"Yilmaz","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Imaging, University Hospital M\u00fcnster,\u00a048149,\u00a0M\u00fcnster,\u00a0Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noel","family":"Dasgupta","sequence":"additional","affiliation":[{"name":"Department of Medicine,\u00a0Indiana University School of Medicine, Indianapolis, IN\u00a046202,\u00a0USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Macey","sequence":"additional","affiliation":[{"name":"Adelphi Values PROVETM, Bollington, Cheshire, UK, SK10 5JB"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Cochrane","sequence":"additional","affiliation":[{"name":"Adelphi Values PROVETM, Bollington, Cheshire, UK, SK10 5JB"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Peatman","sequence":"additional","affiliation":[{"name":"Adelphi Values PROVETM, Bollington, Cheshire, UK, SK10 5JB"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Summers","sequence":"additional","affiliation":[{"name":"Medical Affairs Department, Alnylam Pharmaceuticals, Cambridge, MA\u00a002142,\u00a0USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9332-2163","authenticated-orcid":false,"given":"Jennifer","family":"Luth","sequence":"additional","affiliation":[{"name":"Medical Affairs Department, Alnylam Pharmaceuticals, Cambridge, MA\u00a002142,\u00a0USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Zolty","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine,\u00a0University of Nebraska Medical Center (UNMC), Omaha, NE 68198\u00a0USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"36897","reference":[{"issue":"14","key":"e_1_3_8_3_2","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1001\/jama.1993.03510140062030","article-title":"Prediction of mortality and morbidity with a 6-minute walk test in patients with left ventricular dysfunction","volume":"270","author":"Bittner V","year":"1993","unstructured":"Bittner V, Weiner DH, Yusuf S Prediction of mortality and morbidity with a 6-minute walk test in patients with left ventricular dysfunction. JAMA 270(14), 1702\u20131707 (1993).","journal-title":"JAMA"},{"issue":"1","key":"e_1_3_8_4_2","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1183\/09031936.00194909","article-title":"The 6-min walk distance in healthy subjects: reference standards from seven countries","volume":"37","author":"Casanova C","year":"2011","unstructured":"Casanova C, Celli BR, Barria P The 6-min walk distance in healthy subjects: reference standards from seven countries. Eur. Respir. J. 37(1), 150\u2013156 (2011).","journal-title":"Eur. Respir. J."},{"issue":"4","key":"e_1_3_8_5_2","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.hrtlng.2017.04.001","article-title":"Six-minute walk distance predicts 30-day readmission after acute heart failure hospitalization","volume":"46","author":"McCabe N","year":"2017","unstructured":"McCabe N, Butler J, Dunbar SB, Higgins M, Reilly C. Six-minute walk distance predicts 30-day readmission after acute heart failure hospitalization. Heart Lung 46(4), 287\u2013292 (2017).","journal-title":"Heart Lung"},{"issue":"20","key":"e_1_3_8_6_2","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1016\/j.jacc.2020.09.542","article-title":"Interpreting the Kansas City Cardiomyopathy Questionnaire in clinical trials and clinical care: JACC state-of-the-art review","volume":"76","author":"Spertus JA","year":"2020","unstructured":"Spertus JA, Jones PG, Sandhu AT, Arnold SV. Interpreting the Kansas City Cardiomyopathy Questionnaire in clinical trials and clinical care: JACC state-of-the-art review. J. Am. Coll. Cardiol. 76(20), 2379\u20132390 (2020).","journal-title":"J. Am. Coll. Cardiol."},{"issue":"5","key":"e_1_3_8_7_2","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1164\/ajrccm.158.5.9710086","article-title":"Reference equations for the six-minute walk in healthy adults","volume":"158","author":"Enright PL","year":"1998","unstructured":"Enright PL, Sherrill DL. Reference equations for the six-minute walk in healthy adults. Am. J. Respir. Crit. Care Med. 158(5), 1384\u20131387 (1998).","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"16","key":"e_1_3_8_8_2","doi-asserted-by":"crossref","first-page":"e894","DOI":"10.1161\/CIR.0000000000000483","article-title":"Functional capacity as a principal end point for therapies oriented to older adults with cardiovascular disease: a scientific statement for healthcare professionals from the American Heart Association","volume":"135","author":"Forman DE","year":"2017","unstructured":"Forman DE, Arena R, Boxer R Functional capacity as a principal end point for therapies oriented to older adults with cardiovascular disease: a scientific statement for healthcare professionals from the American Heart Association. Circulation 135(16), e894\u2013e918 (2017).","journal-title":"Circulation"},{"issue":"6","key":"e_1_3_8_9_2","first-page":"429","article-title":"Endpoints in heart failure drug development: history and future","volume":"8","author":"Fiuzat M","year":"2020","unstructured":"Fiuzat M, Lowy N, Stockbridge N Endpoints in heart failure drug development: history and future. JACC. Heart. Fail. 8(6), 429\u2013440 (2020).","journal-title":"JACC. Heart. Fail."},{"key":"e_1_3_8_10_2","unstructured":"European Medicines Agency. Guideline on clinical investigation of medicinal products for the treatment of chronic heart failure (2017). https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-clinical-investigation-medicinal-products-treatment-chronic-heart-failure-revision-2_en.pdf (Accessed: 16 April 2023)."},{"issue":"22","key":"e_1_3_8_11_2","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","article-title":"Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review","volume":"73","author":"Ruberg FL","year":"2019","unstructured":"Ruberg FL, Grogan M, Hanna M, Kelly JW, Maurer MS. Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review. J. Am. Coll. Cardiol. 73(22), 2872\u20132891 (2019).","journal-title":"J. Am. Coll. Cardiol."},{"issue":"10","key":"e_1_3_8_12_2","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1161\/CIRCULATIONAHA.111.078915","article-title":"Transthyretin (TTR) cardiac amyloidosis","volume":"126","author":"Ruberg FL","year":"2012","unstructured":"Ruberg FL, Berk JL. Transthyretin (TTR) cardiac amyloidosis. Circulation 126(10), 1286\u20131300 (2012).","journal-title":"Circulation"},{"issue":"9","key":"e_1_3_8_13_2","doi-asserted-by":"crossref","first-page":"1166.e1","DOI":"10.1016\/j.cjca.2016.05.008","article-title":"Wild-type transthyretin cardiac amyloidosis: novel insights from advanced imaging","volume":"32","author":"Narotsky DL","year":"2016","unstructured":"Narotsky DL, Castano A, Weinsaft JW, Bokhari S, Maurer MS. Wild-type transthyretin cardiac amyloidosis: novel insights from advanced imaging. Can. J. Cardiol. 32(9), 1166.e1\u20131166.e10 (2016).","journal-title":"Can. J. Cardiol."},{"issue":"2","key":"e_1_3_8_14_2","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.ahj.2012.04.015","article-title":"Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: the Transthyretin Amyloidosis Cardiac Study (TRACS)","volume":"164","author":"Ruberg FL","year":"2012","unstructured":"Ruberg FL, Maurer MS, Judge DP Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: the Transthyretin Amyloidosis Cardiac Study (TRACS). Am. Heart J. 164(2), 222\u2013228.e1 (2012).","journal-title":"Am. Heart J."},{"issue":"3","key":"e_1_3_8_15_2","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1161\/CIRCULATIONAHA.115.018852","article-title":"Heart failure resulting from age-related cardiac amyloid disease associated with wild-type transthyretin: a prospective, observational cohort study","volume":"133","author":"Connors LH","year":"2016","unstructured":"Connors LH, Sam F, Skinner M Heart failure resulting from age-related cardiac amyloid disease associated with wild-type transthyretin: a prospective, observational cohort study. Circulation 133(3), 282\u2013290 (2016).","journal-title":"Circulation"},{"issue":"1","key":"e_1_3_8_16_2","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1161\/CIRCULATIONAHA.118.038169","article-title":"Natural history, quality of life, and outcome in cardiac transthyretin amyloidosis","volume":"140","author":"Lane T","year":"2019","unstructured":"Lane T, Fontana M, Martinez-Naharro A Natural history, quality of life, and outcome in cardiac transthyretin amyloidosis. Circulation 140(1), 16\u201326 (2019).","journal-title":"Circulation"},{"issue":"2","key":"e_1_3_8_17_2","doi-asserted-by":"crossref","first-page":"e000098","DOI":"10.1161\/JAHA.113.000098","article-title":"Senile systemic amyloidosis: clinical features at presentation and outcome","volume":"2","author":"Pinney JH","year":"2013","unstructured":"Pinney JH, Whelan CJ, Petrie A Senile systemic amyloidosis: clinical features at presentation and outcome. J. Am. Heart. Assoc. 2(2), e000098 (2013).","journal-title":"J. Am. Heart. Assoc."},{"issue":"9","key":"e_1_3_8_18_2","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1093\/eurheartj\/ehr383","article-title":"Cardiac phenotype and clinical outcome of familial amyloid polyneuropathy associated with transthyretin alanine 60 variant","volume":"33","author":"Sattianayagam PT","year":"2012","unstructured":"Sattianayagam PT, Hahn AF, Whelan CJ Cardiac phenotype and clinical outcome of familial amyloid polyneuropathy associated with transthyretin alanine 60 variant. Eur. Heart J. 33(9), 1120\u20131127 (2012).","journal-title":"Eur. Heart J."},{"issue":"10","key":"e_1_3_8_19_2","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.jacc.2016.06.033","article-title":"Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system","volume":"68","author":"Grogan M","year":"2016","unstructured":"Grogan M, Scott CG, Kyle RA Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system. J. Am. Coll. Cardiol. 68(10), 1014\u20131020 (2016).","journal-title":"J. Am. Coll. Cardiol."},{"issue":"2","key":"e_1_3_8_20_2","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1007\/s00392-017-1167-1","article-title":"Predictors of survival stratification in patients with wild-type cardiac amyloidosis","volume":"107","author":"Aus dem Siepen F","year":"2018","unstructured":"Aus dem Siepen F, Bauer R, Voss A Predictors of survival stratification in patients with wild-type cardiac amyloidosis. Clin. Res. Cardiol. 107(2), 158\u2013169 (2018).","journal-title":"Clin. Res. Cardiol."},{"issue":"2","key":"e_1_3_8_21_2","doi-asserted-by":"crossref","first-page":"229","DOI":"10.2217\/ahe.13.10","article-title":"Comparison of cardiac amyloidosis due to wild-type and V122I transthyretin in older adults referred to an academic medical center","volume":"9","author":"Givens RC","year":"2013","unstructured":"Givens RC, Russo C, Green P Comparison of cardiac amyloidosis due to wild-type and V122I transthyretin in older adults referred to an academic medical center. Aging Health 9(2), 229\u2013235 (2013).","journal-title":"Aging Health"},{"issue":"30","key":"e_1_3_8_22_2","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1093\/eurheartj\/ehx589","article-title":"A new staging system for cardiac transthyretin amyloidosis","volume":"39","author":"Gillmore JD","year":"2018","unstructured":"Gillmore JD, Damy T, Fontana M A new staging system for cardiac transthyretin amyloidosis. Eur. Heart J. 39(30), 2799\u20132806 (2018).","journal-title":"Eur. Heart J."},{"issue":"17","key":"e_1_3_8_23_2","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Heidenreich PA","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D 2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. J. Am. Coll. Cardiol. 79(17), e263\u2013e421 (2022).","journal-title":"J. Am. Coll. Cardiol."},{"issue":"1","key":"e_1_3_8_24_2","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1164\/ajrccm.166.1.at1102","article-title":"ATS statement: guidelines for the six-minute walk test","volume":"166","author":"ATS Board Of Directors","year":"2002","unstructured":"ATS Board Of Directors. ATS statement: guidelines for the six-minute walk test. Am. J. Respir. Crit. Care Med. 166(1), 111\u2013117 (2002).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"e_1_3_8_25_2","first-page":"505969","article-title":"The long-term prognostic significance of 6-minute walk test distance in patients with chronic heart failure","author":"Ingle L","year":"2014","unstructured":"Ingle L, Cleland JG, Clark AL. The long-term prognostic significance of 6-minute walk test distance in patients with chronic heart failure. BioMed. Res. Int. 505969 (2014).","journal-title":"BioMed. Res. Int."},{"issue":"2","key":"e_1_3_8_26_2","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1177\/2047487317735715","article-title":"Gait speed has comparable prognostic capability to six-minute walk distance in older patients with cardiovascular disease","volume":"25","author":"Kamiya K","year":"2018","unstructured":"Kamiya K, Hamazaki N, Matsue Y Gait speed has comparable prognostic capability to six-minute walk distance in older patients with cardiovascular disease. Eur. J. Prev. Cardiol. 25(2), 212\u2013219 (2018).","journal-title":"Eur. J. Prev. Cardiol."},{"issue":"3","key":"e_1_3_8_27_2","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S1836-9553(13)70182-6","article-title":"Distance covered during a six-minute walk test predicts long-term cardiovascular mortality and hospitalisation rates in men with systolic heart failure: an observational study","volume":"59","author":"Wegrzynowska-Teodorczyk K","year":"2013","unstructured":"Wegrzynowska-Teodorczyk K, Rudzinska E, Lazorczyk M Distance covered during a six-minute walk test predicts long-term cardiovascular mortality and hospitalisation rates in men with systolic heart failure: an observational study. J. Physiother. 59(3), 177\u2013187 (2013).","journal-title":"J. Physiother."},{"key":"e_1_3_8_28_2","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1182\/blood-2020-137036","article-title":"The prognostic importance of the 6-minute walk test in AL amyloidosis","volume":"136","author":"Cohen OC","year":"2020","unstructured":"Cohen OC, Sathyanath A, Ravichandran S The prognostic importance of the 6-minute walk test in AL amyloidosis. Blood 136, 16\u201317 (2020).","journal-title":"Blood"},{"issue":"3","key":"e_1_3_8_29_2","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/bjh.14586","article-title":"The six-minute walk test in patients with AL amyloidosis: a single centre case series","volume":"177","author":"Pulido V","year":"2017","unstructured":"Pulido V, Doros G, Berk JL, Sanchorawala V. The six-minute walk test in patients with AL amyloidosis: a single centre case series. Br. J. Haematol. 177(3), 388\u2013394 (2017).","journal-title":"Br. J. Haematol."},{"issue":"24","key":"e_1_3_8_30_2","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1016\/j.jacc.2016.09.936","article-title":"Natriuretic peptides, 6-min walk test, and quality-of-life questionnaires as clinically meaningful endpoints in HF trials","volume":"68","author":"Ferreira JP","year":"2016","unstructured":"Ferreira JP, Duarte K, Graves TL Natriuretic peptides, 6-min walk test, and quality-of-life questionnaires as clinically meaningful endpoints in HF trials. J. Am. Coll. Cardiol. 68(24), 2690\u20132707 (2016).","journal-title":"J. Am. Coll. Cardiol."},{"issue":"3","key":"e_1_3_8_31_2","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1080\/13506129.2022.2052838","article-title":"Guidelines and new directions in the therapy and monitoring of ATTRv amyloidosis","volume":"29","author":"Ando Y","year":"2022","unstructured":"Ando Y, Adams D, Benson MD Guidelines and new directions in the therapy and monitoring of ATTRv amyloidosis. Amyloid 29(3), 143\u2013155 (2022).","journal-title":"Amyloid"},{"issue":"6","key":"e_1_3_8_32_2","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1002\/ejhf.2198","article-title":"Expert consensus on the monitoring of transthyretin amyloid cardiomyopathy","volume":"23","author":"Garcia-Pavia P","year":"2021","unstructured":"Garcia-Pavia P, Bengel F, Brito D Expert consensus on the monitoring of transthyretin amyloid cardiomyopathy. Eur. J. Heart. Fail. 23(6), 895\u2013905 (2021).","journal-title":"Eur. J. Heart. Fail."},{"issue":"5","key":"e_1_3_8_33_2","first-page":"375","article-title":"ATTRv amyloidosis with early improvement demonstrated by the 6-minute walk test following Patisiran therapy: a case report","volume":"62","author":"Oginezawa S","year":"2022","unstructured":"Oginezawa S, Ishihara T, Iwafuchi Y, Hatano Y, Kashimura K, Onodera O. ATTRv amyloidosis with early improvement demonstrated by the 6-minute walk test following Patisiran therapy: a case report. Clin. Neurol. 62(5), 375\u2013379 (2022).","journal-title":"Clin. Neurol."},{"issue":"3","key":"e_1_3_8_34_2","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/jns.12403","article-title":"Peripheral neuropathy symptoms in wild type transthyretin amyloidosis","volume":"25","author":"Yungher FW","year":"2020","unstructured":"Yungher FW, Kim A, Boehme A Peripheral neuropathy symptoms in wild type transthyretin amyloidosis. J. Peripher. Nerv. Syst. 25(3), 265\u2013272 (2020).","journal-title":"J. Peripher. Nerv. Syst."},{"key":"e_1_3_8_35_2","unstructured":"Food and Drug Administration. Treatment for heart failure: endpoints for drug development guidance for industry (2019). https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/treatment-heart-failure-endpoints-drug-development-guidance-industry (Accessed: 16 April 2024)."},{"key":"e_1_3_8_36_2","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372, n71 (2021).","journal-title":"BMJ"},{"key":"e_1_3_8_37_2","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Akl E","year":"2019","unstructured":"Akl E, Altman DG, Aluko P Cochrane Handbook for Systematic Reviews of Interventions. John Wiley & Sons, NJ, USA (2019)."},{"issue":"3","key":"e_1_3_8_38_2","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/XEB.0000000000000054","article-title":"Methodological guidance for systematic reviews of observational epidemiological studies reporting prevalence and cumulative incidence data","volume":"13","author":"Munn Z","year":"2015","unstructured":"Munn Z, Moola S, Lisy K, Riitano D, Tufanaru C. Methodological guidance for systematic reviews of observational epidemiological studies reporting prevalence and cumulative incidence data. Int. J. Evid. Based. Healthc. 13(3), 147\u2013153 (2015).","journal-title":"Int. J. Evid. Based. Healthc."},{"issue":"3","key":"e_1_3_8_39_2","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1002\/ejhf.1404","article-title":"Burden of medical co-morbidities and benefit from surgical revascularization in patients with ischaemic cardiomyopathy","volume":"21","author":"Ambrosy AP","year":"2019","unstructured":"Ambrosy AP, Stevens SR, Al-Khalidi HR Burden of medical co-morbidities and benefit from surgical revascularization in patients with ischaemic cardiomyopathy. Eur. J. Heart. Fail. 21(3), 373\u2013381 (2019).","journal-title":"Eur. J. Heart. Fail."},{"issue":"3","key":"e_1_3_8_40_2","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1016\/j.ijcard.2013.01.157","article-title":"Heart failure biomarkers in patients with dilated cardiomyopathy","volume":"168","author":"Bielecka-Dabrowa A","year":"2013","unstructured":"Bielecka-Dabrowa A, von Haehling S, Aronow WS, Ahmed MI, Rysz J, Banach M. Heart failure biomarkers in patients with dilated cardiomyopathy. Int. J. Cardiol. 168(3), 2404\u20132410 (2013).","journal-title":"Int. J. Cardiol."},{"issue":"3","key":"e_1_3_8_41_2","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s00246-016-1536-y","article-title":"Six-minute walk test as a predictor for outcome in children with dilated cardiomyopathy and chronic stable heart failure","volume":"38","author":"den Boer SL","year":"2017","unstructured":"den Boer SL, Flipse DHK, van der Meulen MH Six-minute walk test as a predictor for outcome in children with dilated cardiomyopathy and chronic stable heart failure. Pediatr. Cardiol. 38(3), 465\u2013471 (2017).","journal-title":"Pediatr. Cardiol."},{"issue":"13","key":"e_1_3_8_42_2","doi-asserted-by":"crossref","first-page":"e008649","DOI":"10.1161\/JAHA.117.008649","article-title":"Clinical outcomes of autologous stem cell-patch implantation for patients with heart failure with nonischemic dilated cardiomyopathy","volume":"10","author":"Domae K","year":"2021","unstructured":"Domae K, Miyagawa S, Yoshikawa Y Clinical outcomes of autologous stem cell-patch implantation for patients with heart failure with nonischemic dilated cardiomyopathy. J. Am. Heart. Assoc. 10(13), e008649 (2021).","journal-title":"J. Am. Heart. Assoc."},{"issue":"4","key":"e_1_3_8_43_2","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/jcsm.12193","article-title":"Muscle wasting in young patients with dilated cardiomyopathy","volume":"8","author":"Hajahmadi M","year":"2017","unstructured":"Hajahmadi M, Shemshadi S, Khalilipur E Muscle wasting in young patients with dilated cardiomyopathy. J. Cachexia Sarcopenia Muscle 8(4), 542\u2013548 (2017).","journal-title":"J. Cachexia Sarcopenia Muscle"},{"issue":"1","key":"e_1_3_8_44_2","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1001\/jama.2013.282909","article-title":"Transendocardial mesenchymal stem cells and mononuclear bone marrow cells for ischemic cardiomyopathy: the TAC-HFT randomized trial","volume":"311","author":"Heldman AW","year":"2014","unstructured":"Heldman AW, DiFede DL, Fishman JE Transendocardial mesenchymal stem cells and mononuclear bone marrow cells for ischemic cardiomyopathy: the TAC-HFT randomized trial. JAMA 311(1), 62\u201373 (2014).","journal-title":"JAMA"},{"issue":"4","key":"e_1_3_8_45_2","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1016\/j.ymthe.2021.01.004","article-title":"Long-term outcomes of autologous skeletal myoblast cell-sheet transplantation for end-stage ischemic cardiomyopathy","volume":"29","author":"Kainuma S","year":"2021","unstructured":"Kainuma S, Miyagawa S, Toda K Long-term outcomes of autologous skeletal myoblast cell-sheet transplantation for end-stage ischemic cardiomyopathy. Mol. Ther. 29(4), 1425\u20131438 (2021).","journal-title":"Mol. Ther."},{"issue":"42","key":"e_1_3_8_46_2","doi-asserted-by":"crossref","first-page":"2898","DOI":"10.1093\/eurheartj\/ehv477","article-title":"Multicentre, randomized, double-blind trial of intracoronary autologous mononuclear bone marrow cell injection in non-ischaemic dilated cardiomyopathy (the dilated cardiomyopathy arm of the MiHeart study)","volume":"36","author":"Martino H","year":"2015","unstructured":"Martino H, Brofman P, Greco O Multicentre, randomized, double-blind trial of intracoronary autologous mononuclear bone marrow cell injection in non-ischaemic dilated cardiomyopathy (the dilated cardiomyopathy arm of the MiHeart study). Eur. Heart J. 36(42), 2898\u20132904 (2015).","journal-title":"Eur. Heart J."},{"issue":"11","key":"e_1_3_8_47_2","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer MS","year":"2018","unstructured":"Maurer MS, Schwartz JH, Gundapaneni B Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N. Engl. J. Med. 379(11), 1007\u20131016 (2018).","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"e_1_3_8_48_2","doi-asserted-by":"crossref","first-page":"e003918","DOI":"10.1161\/JAHA.116.003918","article-title":"Phase I clinical trial of autologous stem cell-sheet transplantation therapy for treating cardiomyopathy","volume":"6","author":"Miyagawa S","year":"2017","unstructured":"Miyagawa S, Domae K, Yoshikawa Y Phase I clinical trial of autologous stem cell-sheet transplantation therapy for treating cardiomyopathy. J. Am. Heart. Assoc. 6(4), e003918 (2017).","journal-title":"J. Am. Heart. Assoc."},{"issue":"3","key":"e_1_3_8_49_2","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1002\/ehf2.13295","article-title":"Serum potassium levels provide prognostic information in symptomatic heart failure beyond traditional clinical variables","volume":"8","author":"Toledo CC","year":"2021","unstructured":"Toledo CC, Schwartzmann PV, Silva LM Serum potassium levels provide prognostic information in symptomatic heart failure beyond traditional clinical variables. ESC. Heart. Fail. 8(3), 2133\u20132143 (2021).","journal-title":"ESC. Heart. Fail."},{"issue":"2","key":"e_1_3_8_50_2","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s00246-019-02244-7","article-title":"Does repeated measurement of a 6-min walk test contribute to risk prediction in children with dilated cardiomyopathy?","volume":"41","author":"van der Meulen MH","year":"2020","unstructured":"van der Meulen MH, den Boer S, du Marchie Sarvaas GJ Does repeated measurement of a 6-min walk test contribute to risk prediction in children with dilated cardiomyopathy? Pediatr. Cardiol. 41(2), 223\u2013229 (2020).","journal-title":"Pediatr. Cardiol."},{"key":"e_1_3_8_51_2","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ijcard.2018.06.041","article-title":"Two-year cardiac mortality after MitraClip treatment of functional mitral regurgitation in ischemic and non-ischemic dilated cardiomyopathy","volume":"269","author":"Godino C","year":"2018","unstructured":"Godino C, Scotti A, Taramasso M Two-year cardiac mortality after MitraClip treatment of functional mitral regurgitation in ischemic and non-ischemic dilated cardiomyopathy. Int. J. Cardiol. 269, 33\u201339 (2018).","journal-title":"Int. J. Cardiol."},{"issue":"5","key":"e_1_3_8_52_2","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.jacc.2016.11.009","article-title":"Randomized comparison of allogeneic versus autologous mesenchymal stem cells for nonischemic dilated cardiomyopathy: POSEIDON-DCM trial","volume":"69","author":"Hare JM","year":"2017","unstructured":"Hare JM, DiFede DL, Rieger AC Randomized comparison of allogeneic versus autologous mesenchymal stem cells for nonischemic dilated cardiomyopathy: POSEIDON-DCM trial. J. Am. Coll. Cardiol. 69(5), 526\u2013537 (2017).","journal-title":"J. Am. Coll. Cardiol."},{"issue":"8","key":"e_1_3_8_53_2","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1161\/CIRCRESAHA.115.304554","article-title":"Safety and efficacy of ixmyelocel-T: an expanded, autologous multi-cellular therapy, in dilated cardiomyopathy","volume":"115","author":"Henry TD","year":"2014","unstructured":"Henry TD, Traverse JH, Hammon BL Safety and efficacy of ixmyelocel-T: an expanded, autologous multi-cellular therapy, in dilated cardiomyopathy. Circ. Res. 115(8), 730\u2013737 (2014).","journal-title":"Circ. Res."},{"issue":"3","key":"e_1_3_8_54_2","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2298\/VSP140109071T","article-title":"Functional recovery of patients with ischemic cardiomyopathy treated with coronary artery bypass surgery and concomitant intramyocardial bone marrow mononuclear cell implantation\u2014a long-term follow-up study","volume":"72","author":"Trifunovic Z","year":"2015","unstructured":"Trifunovic Z, Obradovic S, Balint B Functional recovery of patients with ischemic cardiomyopathy treated with coronary artery bypass surgery and concomitant intramyocardial bone marrow mononuclear cell implantation\u2014a long-term follow-up study. Vojnosanit. Pregl. 72(3), 225\u2013232 (2015).","journal-title":"Vojnosanit. Pregl."},{"issue":"1","key":"e_1_3_8_55_2","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1161\/CIRCRESAHA.112.276519","article-title":"Effects of intracoronary CD34+ stem cell transplantation in nonischemic dilated cardiomyopathy patients: 5-year follow-up","volume":"112","author":"Vrtovec B","year":"2013","unstructured":"Vrtovec B, Poglajen G, Lezaic L Effects of intracoronary CD34+ stem cell transplantation in nonischemic dilated cardiomyopathy patients: 5-year follow-up. Circ. Res. 112(1), 165\u2013173 (2013).","journal-title":"Circ. Res."},{"key":"e_1_3_8_56_2","first-page":"373","article-title":"Long-term effects of stem cell transplantation in heart failure","volume":"81","author":"Vrtovec B","year":"2012","unstructured":"Vrtovec B, Sever M, Domanovic D Long-term effects of stem cell transplantation in heart failure. Zdrav. Vestn. 81, 373\u2013383 (2012).","journal-title":"Zdrav. Vestn."},{"issue":"2","key":"e_1_3_8_57_2","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1536\/ihj.16-328","article-title":"A randomized comparative study on the efficacy of intracoronary infusion of autologous bone marrow mononuclear cells and mesenchymal stem cells in patients with dilated cardiomyopathy","volume":"58","author":"Xiao W","year":"2017","unstructured":"Xiao W, Guo S, Gao C A randomized comparative study on the efficacy of intracoronary infusion of autologous bone marrow mononuclear cells and mesenchymal stem cells in patients with dilated cardiomyopathy. Int. Heart J. 58(2), 238\u2013244 (2017).","journal-title":"Int. Heart J."},{"issue":"3","key":"e_1_3_8_58_2","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s10557-019-06919-4","article-title":"Phase III multicenter study of Revusiran in patients with hereditary transthyretin-mediated (hATTR) amyloidosis with cardiomyopathy (ENDEAVOUR)","volume":"34","author":"Judge DP","year":"2020","unstructured":"Judge DP, Kristen AV, Grogan M Phase III multicenter study of Revusiran in patients with hereditary transthyretin-mediated (hATTR) amyloidosis with cardiomyopathy (ENDEAVOUR). Cardiovasc. Drugs Ther. 34(3), 357\u2013370 (2020).","journal-title":"Cardiovasc. Drugs Ther."},{"issue":"5","key":"e_1_3_8_59_2","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.jchf.2014.04.014","article-title":"Ambulatory extra-aortic counterpulsation in patients with moderate to severe chronic heart failure","volume":"2","author":"Abraham WT","year":"2014","unstructured":"Abraham WT, Aggarwal S, Prabhu SD Ambulatory extra-aortic counterpulsation in patients with moderate to severe chronic heart failure. JACC. Heart Fail. 2(5), 526\u2013533 (2014).","journal-title":"JACC. Heart Fail."},{"key":"e_1_3_8_60_2","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/1476-511X-12-47","article-title":"The influence of atorvastatin on parameters of inflammation left ventricular function, hospitalizations and mortality in patients with dilated cardiomyopathy \u2013 5-year follow-up","volume":"12","author":"Bielecka-Dabrowa A","year":"2013","unstructured":"Bielecka-Dabrowa A, Mikhailidis DP, Rizzo M, von Haehling S, Rysz J, Banach M. The influence of atorvastatin on parameters of inflammation left ventricular function, hospitalizations and mortality in patients with dilated cardiomyopathy \u2013 5-year follow-up. Lipids Health Dis. 12, 47 (2013).","journal-title":"Lipids Health Dis."},{"issue":"2","key":"e_1_3_8_61_2","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1002\/sctm.17-0197","article-title":"CD34(+) cell transplantation improves right ventricular function in patients with nonischemic dilated cardiomyopathy","volume":"7","author":"Frljak S","year":"2018","unstructured":"Frljak S, Jaklic M, Zemljic G, Cerar A, Poglajen G, Vrtovec B. CD34(+) cell transplantation improves right ventricular function in patients with nonischemic dilated cardiomyopathy. Stem Cells Transl. Med. 7(2), 168\u2013172 (2018).","journal-title":"Stem Cells Transl. Med."},{"key":"e_1_3_8_62_2","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ijcard.2018.10.086","article-title":"Cardiac contractility modulation treatment in patients with symptomatic heart failure despite optimal medical therapy and cardiac resynchronization therapy (CRT)","volume":"277","author":"Kuschyk J","year":"2019","unstructured":"Kuschyk J, Nagele H, Heinz-Kuck K Cardiac contractility modulation treatment in patients with symptomatic heart failure despite optimal medical therapy and cardiac resynchronization therapy (CRT). Int. J. Cardiol. 277, 173\u2013177 (2019).","journal-title":"Int. J. Cardiol."},{"issue":"5","key":"e_1_3_8_63_2","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1093\/europace\/euv287","article-title":"The clinical outcome of cardiac resynchronization therapy in post-surgical valvular cardiomyopathy","volume":"18","author":"Leyva F","year":"2016","unstructured":"Leyva F, Umar F, Taylor RJ, Steeds RP, Frenneaux MP. The clinical outcome of cardiac resynchronization therapy in post-surgical valvular cardiomyopathy. Europace 18(5), 732\u2013738 (2016).","journal-title":"Europace"},{"issue":"1","key":"e_1_3_8_64_2","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1186\/s12872-021-02414-7","article-title":"Impact of autoantibodies against the M2-muscarinic acetylcholine receptor on clinical outcomes in peripartum cardiomyopathy patients with standard treatment","volume":"21","author":"Ma G","year":"2021","unstructured":"Ma G, Chen L, Yue Y Impact of autoantibodies against the M2-muscarinic acetylcholine receptor on clinical outcomes in peripartum cardiomyopathy patients with standard treatment. BMC Cardiovasc. Disord. 21(1), 619 (2021).","journal-title":"BMC Cardiovasc. Disord."},{"issue":"3","key":"e_1_3_8_65_2","first-page":"437","article-title":"Direct intramyocardial transthoracic transplantation of bone marrow mononuclear cells for non-ischemic dilated cardiomyopathy: INTRACELL, a prospective randomized controlled trial","volume":"29","author":"Sant'Anna RT","year":"2014","unstructured":"Sant'Anna RT, Fracasso J, Valle FH Direct intramyocardial transthoracic transplantation of bone marrow mononuclear cells for non-ischemic dilated cardiomyopathy: INTRACELL, a prospective randomized controlled trial. Rev. Bras. Cir. Cardiovasc. 29(3), 437\u2013447 (2014).","journal-title":"Rev. Bras. Cir. Cardiovasc."},{"issue":"3","key":"e_1_3_8_66_2","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1161\/CIRCRESAHA.117.312170","article-title":"Effects of repetitive transendocardial CD34(+) cell transplantation in patients with nonischemic dilated cardiomyopathy","volume":"123","author":"Vrtovec B","year":"2018","unstructured":"Vrtovec B, Poglajen G, Sever M Effects of repetitive transendocardial CD34(+) cell transplantation in patients with nonischemic dilated cardiomyopathy. Circ. Res. 123(3), 389\u2013396 (2018).","journal-title":"Circ. Res."},{"issue":"5","key":"e_1_3_8_67_2","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s40256-021-00464-y","article-title":"Modeling of survival and frequency of cardiovascular-related hospitalization in patients with transthyretin amyloid cardiomyopathy treated with Tafamidis","volume":"21","author":"Vong C","year":"2021","unstructured":"Vong C, Boucher M, Riley S Modeling of survival and frequency of cardiovascular-related hospitalization in patients with transthyretin amyloid cardiomyopathy treated with Tafamidis. Am. J. Cardiovasc. Drugs. 21(5), 535\u2013543 (2021).","journal-title":"Am. J. Cardiovasc. Drugs."},{"issue":"1","key":"e_1_3_8_68_2","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1097\/01823246-201021010-00003","article-title":"Examination of the six minute walk test to determine functional capacity in people with chronic heart failure: a systematic review","volume":"21","author":"Pollentier B","year":"2010","unstructured":"Pollentier B, Irons SL, Benedetto CM Examination of the six minute walk test to determine functional capacity in people with chronic heart failure: a systematic review. Cardiopulm. Phys. Ther. J. 21(1), 13\u201321 (2010).","journal-title":"Cardiopulm. Phys. Ther. J."},{"key":"e_1_3_8_69_2","doi-asserted-by":"crossref","first-page":"RRN1297","DOI":"10.1371\/currents.RRN1297","article-title":"Percent-predicted 6-minute walk distance in Duchenne muscular dystrophy to account for maturational influences","volume":"4","author":"Henricson E","year":"2012","unstructured":"Henricson E, Abresch R, Han JJ Percent-predicted 6-minute walk distance in Duchenne muscular dystrophy to account for maturational influences. PloS Curr. 4, RRN1297 (2012).","journal-title":"PloS Curr."},{"key":"e_1_3_8_70_2","doi-asserted-by":"crossref","first-page":"ehaa946.2115","DOI":"10.1093\/ehjci\/ehaa946.2115","article-title":"Benefits of tafamidis in patients with advanced transthyretin amyloid cardiomyopathy","volume":"41","author":"Rapezzi C","year":"2020","unstructured":"Rapezzi C, Kristen AV, Gundapaneni B, Sultan MB, Hanna M. Benefits of tafamidis in patients with advanced transthyretin amyloid cardiomyopathy. Eur. Heart J. 41, ehaa946.2115 (2020).","journal-title":"Eur. Heart J."},{"issue":"5","key":"e_1_3_8_71_2","doi-asserted-by":"crossref","first-page":"3875","DOI":"10.1002\/ehf2.13541","article-title":"Natural history and progression of transthyretin amyloid cardiomyopathy: insights from ATTR-ACT","volume":"8","author":"Nativi-Nicolau J","year":"2021","unstructured":"Nativi-Nicolau J, Judge DP, Hoffman JE Natural history and progression of transthyretin amyloid cardiomyopathy: insights from ATTR-ACT. ESC Heart Fail. 8(5), 3875\u20133884 (2021).","journal-title":"ESC Heart Fail."},{"issue":"2","key":"e_1_3_8_72_2","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jchf.2020.09.011","article-title":"Efficacy of tafamidis in patients with hereditary and wild-type transthyretin amyloid cardiomyopathy: further analyses from ATTR-ACT","volume":"9","author":"Rapezzi C","year":"2021","unstructured":"Rapezzi C, Elliott P, Damy T Efficacy of tafamidis in patients with hereditary and wild-type transthyretin amyloid cardiomyopathy: further analyses from ATTR-ACT. JACC Heart Fail. 9(2), 115\u2013123 (2021).","journal-title":"JACC Heart Fail."},{"issue":"10","key":"e_1_3_8_73_2","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/j.cardfail.2020.09.037","article-title":"Efficacy of tafamidis by baseline 6-minute walk test distance in the tafamidis in transthyretin cardiomyopathy clinical trial (ATTR-ACT)","volume":"26","author":"Maurer MS","year":"2020","unstructured":"Maurer MS, Adler E, Gundapaneni B, Sultan MB, Rapezzi C. Efficacy of tafamidis by baseline 6-minute walk test distance in the tafamidis in transthyretin cardiomyopathy clinical trial (ATTR-ACT). J. Card. Fail. 26(10), S10 (2020).","journal-title":"J. Card. Fail."},{"issue":"7","key":"e_1_3_8_74_2","first-page":"CD013433","article-title":"Stem cell therapy for dilated cardiomyopathy","volume":"7","author":"Diaz-Navarro R","year":"2021","unstructured":"Diaz-Navarro R, Urrutia G, Cleland J Gf Stem cell therapy for dilated cardiomyopathy. Cochrane Database Syst. Rev. 7(7), CD013433 (2021).","journal-title":"Cochrane Database Syst. Rev."},{"issue":"12","key":"e_1_3_8_75_2","first-page":"1463","article-title":"Effects of stem cell therapy on dilated cardiomyopathy","volume":"35","author":"Jiao R","year":"2014","unstructured":"Jiao R, Liu Y, Yang W-J, Zhu X-Y, Li J, Tang Q-Z. Effects of stem cell therapy on dilated cardiomyopathy. Saudi. Medical J. 35(12), 1463\u20131468 (2014).","journal-title":"Saudi. Medical J."},{"issue":"1","key":"e_1_3_8_76_2","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1186\/s13287-016-0441-x","article-title":"A systematic review of randomised controlled trials examining the therapeutic effects of adult bone marrow-derived stem cells for non-ischaemic dilated cardiomyopathy","volume":"7","author":"Lu Y","year":"2016","unstructured":"Lu Y, Wang Y, Lin M A systematic review of randomised controlled trials examining the therapeutic effects of adult bone marrow-derived stem cells for non-ischaemic dilated cardiomyopathy. Stem Cell Res. Ther. 7(1), 186 (2016).","journal-title":"Stem Cell Res. Ther."},{"issue":"1","key":"e_1_3_8_77_2","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s13287-019-1238-5","article-title":"Safety and efficacy of bone marrow-derived cells therapy on cardiomyopathy: a meta-analysis","volume":"10","author":"Wang C","year":"2019","unstructured":"Wang C, Li J, Zhang B, Li Y. Safety and efficacy of bone marrow-derived cells therapy on cardiomyopathy: a meta-analysis. Stem Cell Res. Ther. 10(1), 137 (2019).","journal-title":"Stem Cell Res. Ther."},{"issue":"12","key":"e_1_3_8_78_2","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.jcyt.2020.06.006","article-title":"Effects of stem cells on non-ischemic cardiomyopathy: a systematic review and meta-analysis of randomized controlled trials","volume":"22","author":"Xia L","year":"2020","unstructured":"Xia L, Zeng L, Pan J, Ding Y. Effects of stem cells on non-ischemic cardiomyopathy: a systematic review and meta-analysis of randomized controlled trials. Cytotherapy 22(12), 699\u2013711 (2020).","journal-title":"Cytotherapy"},{"key":"e_1_3_8_79_2","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1186\/s12967-019-1966-4","article-title":"Efficacy and safety of stem cell therapy in patients with dilated cardiomyopathy: a systematic appraisal and meta-analysis","volume":"17","author":"Rong S-L","year":"2019","unstructured":"Rong S-L, Wang Z-K, Zhou X-D, Wang X-L, Yang Z-M, Li B. Efficacy and safety of stem cell therapy in patients with dilated cardiomyopathy: a systematic appraisal and meta-analysis. J. Transl. Med. 17, 221 (2019).","journal-title":"J. Transl. Med."},{"issue":"4","key":"e_1_3_8_80_2","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1080\/13506129.2017.1374946","article-title":"Safety and efficacy of a TTR specific antisense oligonucleotide in patients with transthyretin amyloid cardiomyopathy","volume":"24","author":"Benson MD","year":"2017","unstructured":"Benson MD, Dasgupta NR, Rissing SM, Smith J, Feigenbaum H. Safety and efficacy of a TTR specific antisense oligonucleotide in patients with transthyretin amyloid cardiomyopathy. Amyloid 24(4), 217\u2013223 (2017).","journal-title":"Amyloid"},{"key":"e_1_3_8_81_2","unstructured":"ClinicalTrials.gov. APOLLO-B: a study to evaluate patisiran in participants with transthyretin amyloidosis with cardiomyopathy (ATTR amyloidosis with cardiomyopathy) (2022). https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03997383 (Accessed: 16 April 2024)."},{"issue":"3","key":"e_1_3_8_82_2","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s10741-021-10098-6","article-title":"Clinical comparison of V122I genotypic variant of transthyretin amyloid cardiomyopathy with wild-type and other hereditary variants: a systematic review","volume":"27","author":"Goyal A","year":"2022","unstructured":"Goyal A, Lahan S, Dalia T Clinical comparison of V122I genotypic variant of transthyretin amyloid cardiomyopathy with wild-type and other hereditary variants: a systematic review. Heart. Fail. Rev. 27(3), 849\u2013856 (2022).","journal-title":"Heart. Fail. Rev."},{"issue":"6","key":"e_1_3_8_83_2","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1183\/09031936.00155009","article-title":"The role of per cent predicted 6-min walk distance in pulmonary arterial hypertension","volume":"36","author":"Lee W-TN","year":"2010","unstructured":"Lee W-TN, Peacock AJ, Johnson MK. The role of per cent predicted 6-min walk distance in pulmonary arterial hypertension. Eur. Respir. J. 36(6), 1294\u20131301 (2010).","journal-title":"Eur. Respir. J."},{"issue":"4","key":"e_1_3_8_84_2","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1007\/s11897-017-0334-z","article-title":"Novel endpoints for heart failure clinical trials","volume":"14","author":"Hamo CE","year":"2017","unstructured":"Hamo CE, Gheorghiade M, Butler J. Novel endpoints for heart failure clinical trials. Curr. Heart. Fail. Rep. 14(4), 210\u2013216 (2017).","journal-title":"Curr. Heart. Fail. Rep."},{"issue":"9","key":"e_1_3_8_85_2","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1164\/rccm.201012-2079ED","article-title":"Strengths and limitations of the six-minute-walk test: a model biomarker study in idiopathic pulmonary fibrosis","volume":"183","author":"Heresi GA","year":"2011","unstructured":"Heresi GA, Dweik RA. Strengths and limitations of the six-minute-walk test: a model biomarker study in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 183(9), 1122\u20131124 (2011).","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"1","key":"e_1_3_8_86_2","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.bjpt.2020.01.001","article-title":"Performance difference on the six-minute walk test on tracks of 20 and 30 meters for patients with chronic obstructive pulmonary disease: validity and reliability","volume":"25","author":"Klein SR","year":"2021","unstructured":"Klein SR, Gulart AA, Venancio RS Performance difference on the six-minute walk test on tracks of 20 and 30 meters for patients with chronic obstructive pulmonary disease: validity and reliability. Braz. J. Phys. Ther. 25(1), 40\u201347 (2021).","journal-title":"Braz. J. Phys. Ther."},{"key":"e_1_3_8_87_2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ejim.2020.09.025","article-title":"Transthyretin amyloid cardiomyopathy: an uncharted territory awaiting discovery","volume":"82","author":"Porcari A","year":"2020","unstructured":"Porcari A, Merlo M, Rapezzi C, Singara G. Transthyretin amyloid cardiomyopathy: an uncharted territory awaiting discovery. Eur. J. Intern. Med. 82, 7\u201315 (2020).","journal-title":"Eur. J. Intern. Med."},{"issue":"8","key":"e_1_3_8_88_2","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.jchf.2019.04.010","article-title":"Screening for transthyretin amyloid cardiomyopathy in everyday practice","volume":"7","author":"Witteles RM","year":"2019","unstructured":"Witteles RM, Bokhari S, Damy T Screening for transthyretin amyloid cardiomyopathy in everyday practice. JACC Heart Fail. 7(8), 709\u2013716 (2019).","journal-title":"JACC Heart Fail."},{"issue":"5","key":"e_1_3_8_89_2","doi-asserted-by":"crossref","first-page":"2904","DOI":"10.1002\/ehf2.12900","article-title":"6 min walk test is a strong independent predictor of death in outpatients with heart failure","volume":"7","author":"Grundtvig M","year":"2020","unstructured":"Grundtvig M, Eriksen-Volnes T, Orn S, Slind EK, Gullestad L. 6 min walk test is a strong independent predictor of death in outpatients with heart failure. ESC Heart Fail. 7(5), 2904\u20132911 (2020).","journal-title":"ESC Heart Fail."}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.57264\/cer-2023-0158","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T11:15:45Z","timestamp":1720091745000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.57264\/cer-2023-0158"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":87,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["10.57264\/cer-2023-0158"],"URL":"https:\/\/doi.org\/10.57264\/cer-2023-0158","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"value":"2042-6305","type":"print"},{"value":"2042-6313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7]]},"article-number":"e230158"}}